Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline

  • F. S. Mennini
  • , P. Sciattella
  • , A. Marcellusi
  • , A. Marcobelli
  • , A. Russo
  • , A. P. Caputi

    Research output: Contribution to journalArticlepeer-review

    Abstract

    BACKGROUND: The main objective of this article is to estimate the global cost related to the use of the two drugs (associated drugs, specialist visits, hospital admissions, plasma drug monitoring). METHODS: The drug prescriptions were extracted from the Information System of the Pharmaceutical Prescriptions of the Marche Region for each ATC code in the years 2008-2012 and the number of patients per year and other outcomes measure were obtained. RESULTS: 13,574 patients were treated with theophylline and 19,426 patients with doxophylline. The number of patients treated was approximately 5,000 per year. Co-prescription with other drugs, use of corticosteroids, mean number of visits and hospital admissions (per 100 patients) were lower for doxophylline vs theophylline (1.55vs5.50, 0.3vs0.7, 2.05vs3.73 and 1.57vs3.3 respectively). The annual mean cost per patient was €187.4 for those treated with doxophylline and €513.5 for theophylline. CONCLUSIONS: In our study, doxophylline resulted to be associated with a reduction of the overall cost.
    Original languageEnglish
    Pages (from-to)503-510
    JournalPsychodynamic Practice
    Volume17
    Issue number5
    Early online date15 Mar 2017
    DOIs
    Publication statusPublished - 2017

    Keywords

    • Epidemiology and public health

    Fingerprint

    Dive into the research topics of 'Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline'. Together they form a unique fingerprint.

    Cite this